Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer

NCT00388687UNKNOWNOBSERVATIONAL

Summary

Key Facts

Lead Sponsor

Medical University of Vienna

Enrollment

25

Start Date

2006-07-01

Study Type

OBSERVATIONAL

Official Title

Hypoxia Imaging With the Novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic Impact in Cervical Cancer

Interventions

18F Fluoroazomycin Arabinoside (FAZA)

Conditions

Uterine Cervical Neoplasms

Eligibility

Age Range

18 Years – 80 Years

Sex

FEMALE

Inclusion Criteria:

* First diagnosis of histologically proven cervical cancer FIGO stage IB2 to IVA.
* Treatment intention for the purpose of achieving cure
* Age \< 80 years
* No previous standard or radical hysterectomy

Exclusion Criteria:

* Pregnancy, breast-feeding women, patients that are not able to lie motionless for one hour.Palliative treatment, recurrent disease, neoadjuvant chemotherapy, other pre-existing malignancies, age \> 80 years,

Locations

Medical Universitiy of Vienna, Vienna, Austria

Medical University of Vienna, Vienna, Austria

Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer